Clinical Trial Update: The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) [Phase 3]

View source ↗

Summary

A Phase 3 trial assessed oral azacitidine plus best supportive care versus placebo and best supportive care in transfusion-dependent, low-risk myelodysplastic s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Oral azacitidine (azacitidine (oral formulation))

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2020-02-26